Core Viewpoint - Heng Rui Medicine's stock price has shown a significant increase of 40.02% year-to-date, indicating strong market performance despite recent fluctuations in trading volume and net capital outflow [2][3]. Company Overview - Heng Rui Medicine, established on April 28, 1997, and listed on October 18, 2000, is primarily engaged in the research, production, and sales of pharmaceuticals, focusing on oncology and related fields [2]. - The company's product portfolio includes anti-tumor drugs, analgesics, and contrast agents, with applications across various medical conditions such as autoimmune diseases, cardiovascular diseases, and neurological disorders [2]. Financial Performance - For the first half of 2025, Heng Rui Medicine reported a revenue of 15.76 billion yuan, representing a year-on-year growth of 15.88%, and a net profit attributable to shareholders of 4.45 billion yuan, up 29.67% from the previous year [3]. - The company has distributed a total of 9.30 billion yuan in dividends since its A-share listing, with 3.57 billion yuan distributed over the last three years [4]. Shareholder Structure - As of June 30, 2025, the number of shareholders decreased to 364,700, while the average circulating shares per person increased by 12.70% to 17,493 shares [3]. - Major shareholders include Hong Kong Central Clearing Limited, which holds 535 million shares, and various ETFs that have increased their holdings [4].

Core Viewpoint - Heng Rui Medicine's stock price has shown significant growth this year, with a 45.14% increase, indicating strong market performance and investor interest [2]. Company Overview - Jiangsu Heng Rui Medicine Co., Ltd. is primarily engaged in the research, production, and sales of pharmaceuticals, focusing on oncology and covering various therapeutic areas including pain management and cardiovascular diseases [2]. - The company's revenue composition includes oncology (52.12%), neuroscience (15.33%), imaging agents (9.82%), and other therapeutic areas [2]. Financial Performance - For the first half of 2025, Heng Rui Medicine reported a revenue of 15.76 billion yuan, a year-on-year increase of 15.88%, and a net profit of 4.45 billion yuan, up 29.67% year-on-year [3]. - The company has distributed a total of 9.30 billion yuan in dividends since its A-share listing, with 3.57 billion yuan distributed in the last three years [4]. Stock Market Activity - As of August 25, Heng Rui Medicine's stock price was 66.33 yuan per share, with a market capitalization of 440.25 billion yuan [1]. - The stock has seen a net inflow of 123 million yuan from major funds, indicating strong buying interest [1]. Shareholder Information - As of June 30, 2025, the number of shareholders decreased to 364,700, while the average circulating shares per person increased by 12.70% [3]. - Major shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 14.3 million shares [4].